Literature DB >> 16228185

An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer.

Jeffrey Stephenson1, Andrew Davies.   

Abstract

STUDY AIM: The aim of this study was to assess the effectiveness of aetiology-based guidelines for the management of nausea and vomiting (N&V) in patients with advanced cancer. PATIENTS AND METHODS: This was a prospective study of 121 patients admitted to a hospice. Patients with N&V underwent assessments at presentation, 48 h and 1 week, to determine the aetiology of N&V and the response to treatment. Antiemetics were prescribed according to aetiology-based guidelines.
RESULTS: Sixty-one patients (50%) had N&V during their admission: 21 (17%) had isolated nausea, 2 (2%) had isolated vomiting and 38 (31%) had combined N&V. During the assessment period, physicians altered their opinion about the primary cause of N&V in 26% of cases and finally expressed confidence about the aetiology in 75% of patients. The most common cause of N&V was impaired gastric emptying (contributing in 44% of patients), followed by chemical causes (33%) and bowel obstruction (19%). At 1 week, nausea was controlled in 56% of patients, and vomiting in 89% of patients, and residual symptoms were generally mild.
CONCLUSIONS: An approach using aetiology-based guidelines in the management of N&V is moderately effective, although there are some patients with N&V refractory to standard antiemetic regimens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16228185     DOI: 10.1007/s00520-005-0897-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  6 in total

Review 1.  Strategies to manage the adverse effects of oral morphine: an evidence-based report.

Authors:  N Cherny; C Ripamonti; J Pereira; C Davis; M Fallon; H McQuay; S Mercadante; G Pasternak; V Ventafridda
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

2.  Challenges in palliative care research; recruitment, attrition and compliance: experience from a randomized controlled trial.

Authors:  M S Jordhøy; S Kaasa; P Fayers; T Ovreness; G Underland; M Ahlner-Elmqvist
Journal:  Palliat Med       Date:  1999-07       Impact factor: 4.762

3.  Use of clinical pictures in the management of nausea and vomiting: a prospective audit.

Authors:  A Bentley; K Boyd
Journal:  Palliat Med       Date:  2001-05       Impact factor: 4.762

4.  Results of antiemetic management in terminal illness.

Authors:  I Lichter
Journal:  J Palliat Care       Date:  1993       Impact factor: 2.250

Review 5.  Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer.

Authors:  Paul Glare; Glenn Pereira; Linda J Kristjanson; Martin Stockler; Martin Tattersall
Journal:  Support Care Cancer       Date:  2004-04-24       Impact factor: 3.603

6.  Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia.

Authors:  C L Loprinzi; J C Michalak; D J Schaid; J A Mailliard; L M Athmann; R M Goldberg; L K Tschetter; A K Hatfield; R F Morton
Journal:  J Clin Oncol       Date:  1993-04       Impact factor: 44.544

  6 in total
  21 in total

Review 1.  Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting.

Authors:  Hanno Riess; Cihan Ay; Rupert Bauersachs; Cecilia Becattini; Jan Beyer-Westendorf; Francis Cajfinger; Ian Chau; Alexander T Cohen; Alok A Khorana; Anthony Maraveyas; Marcos Renni; Annie M Young
Journal:  Oncologist       Date:  2018-04-12

Review 2.  Symptom management in metastatic breast cancer.

Authors:  William Irvin; Hyman B Muss; Deborah K Mayer
Journal:  Oncologist       Date:  2011-08-31

3.  Nausea and vomiting in palliative care.

Authors:  Charlotte Leach
Journal:  Clin Med (Lond)       Date:  2019-07       Impact factor: 2.659

Review 4.  Nutrition therapy issues in esophageal cancer.

Authors:  Keith R Miller; Matthew C Bozeman
Journal:  Curr Gastroenterol Rep       Date:  2012-08

Review 5.  2016 Updated MASCC/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer.

Authors:  Declan Walsh; Mellar Davis; Carla Ripamonti; Eduardo Bruera; Andrew Davies; Alex Molassiotis
Journal:  Support Care Cancer       Date:  2016-08-17       Impact factor: 3.603

6.  Predictors of response to palliative care intervention for chronic nausea in advanced cancer outpatients.

Authors:  Wadih Rhondali; Sriram Yennurajalingam; Gary Chisholm; Jeanette Ferrer; Sun Hyun Kim; Jung Hun Kang; Marilene Filbet; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2013-04-16       Impact factor: 3.603

Review 7.  Management of gastrointestinal symptoms in advanced cancer patients: the rapid learning cancer clinic model.

Authors:  Amy P Abernethy; Jane L Wheeler; S Yousuf Zafar
Journal:  Curr Opin Support Palliat Care       Date:  2010-03       Impact factor: 2.302

8.  Palliative venting percutaneous endoscopic gastrostomy tube is safe and effective in patients with malignant obstruction.

Authors:  Rachel B Issaka; David M Shapiro; Neehar D Parikh; Mary F Mulcahy; Srinadh Komanduri; John A Martin; Rajesh N Keswani
Journal:  Surg Endosc       Date:  2013-12-24       Impact factor: 4.584

Review 9.  Role of supportive care for terminal stage hepatocellular carcinoma.

Authors:  Manoj Kumar; Dipanjan Panda
Journal:  J Clin Exp Hepatol       Date:  2014-03-31

10.  Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.

Authors:  Katsunobu Oyama; Sachio Fushida; Masahide Kaji; Toshiya Takeda; Shinichi Kinami; Yasuo Hirono; Katsuhiro Yoshimoto; Kazuhisa Yabushita; Hisashi Hirosawa; Yuki Takai; Tatsuo Nakano; Hironobu Kimura; Toshiaki Yasui; Atsushi Tsuneda; Tomoya Tsukada; Jun Kinoshita; Takashi Fujimura; Tetsuo Ohta
Journal:  J Gastroenterol       Date:  2013-01-22       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.